243 related articles for article (PubMed ID: 18268286)
1. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
Rawstron AC; Orfao A; Beksac M; Bezdickova L; Brooimans RA; Bumbea H; Dalva K; Fuhler G; Gratama J; Hose D; Kovarova L; Lioznov M; Mateo G; Morilla R; Mylin AK; Omedé P; Pellat-Deceunynck C; Perez Andres M; Petrucci M; Ruggeri M; Rymkiewicz G; Schmitz A; Schreder M; Seynaeve C; Spacek M; de Tute RM; Van Valckenborgh E; Weston-Bell N; Owen RG; San Miguel JF; Sonneveld P; Johnsen HE;
Haematologica; 2008 Mar; 93(3):431-8. PubMed ID: 18268286
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice.
Gupta R; Jevremovic D; Mathew SJ; Kumar S
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e88-e95. PubMed ID: 38142203
[TBL] [Abstract][Full Text] [Related]
3. An alternative processing approach to increase CD138 intensity in flow cytometric analysis of plasma cells.
Kumar D; Kiran FNU; Wheeler A; Dellamano R; Hammer RD
Cytometry B Clin Cytom; 2024 Mar; 106(2):113-116. PubMed ID: 38010113
[TBL] [Abstract][Full Text] [Related]
4. Quantification of circulating clonal plasma cells by multiparametric flow cytometry as a prognostic marker in patients with newly diagnosed multiple myeloma.
Sathya P; Kayal S; Srinivas BH; Hamide A; Kar R
Int J Lab Hematol; 2023 Dec; 45(6):917-926. PubMed ID: 37632156
[TBL] [Abstract][Full Text] [Related]
5. Measurable residual disease in multiple myeloma: ready for clinical practice?
Burgos L; Puig N; Cedena MT; Mateos MV; Lahuerta JJ; Paiva B; San-Miguel JF
J Hematol Oncol; 2020 Jun; 13(1):82. PubMed ID: 32571377
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow immunohistology of plasma cell neoplasms.
Wei A; Juneja S
J Clin Pathol; 2003 Jun; 56(6):406-11. PubMed ID: 12783964
[TBL] [Abstract][Full Text] [Related]
7. PCNEO, a New Proficiency Testing Program for Flow Cytometric Analysis of Plasma Cell Neoplasms From the College of American Pathologists Diagnostic Immunology and Flow Cytometry Committee.
Dorfman DM; Devitt KA; Cui W; Bashleben C; Naharro ECF; Hedley B; Hupp M; Karlon WJ; Murphy CE; Cherian S; Olteanu H; Seifert RP; Rosado FN; Linden MA
Arch Pathol Lab Med; 2023 Sep; ():. PubMed ID: 37776247
[TBL] [Abstract][Full Text] [Related]
8. Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters.
Gupta L; Suku P; Dash A; Bose P; Sharma P; Mallik N; Sreedharanunni S; Varma N; Jandial A; Malhotra P; Sachdeva MUS
Curr Probl Cancer; 2024 Feb; 48():101025. PubMed ID: 37951052
[TBL] [Abstract][Full Text] [Related]
9. [Expert consensus on laboratory standardized technical specifications for monitoring minimal residual disease using next-generation sequencing in multiple myeloma(2021)].
;
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):974-977. PubMed ID: 35045666
[No Abstract] [Full Text] [Related]
10. Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry.
Noori S; Wijnands C; Langerhorst P; Bonifay V; Stingl C; Touzeau C; Corre J; Perrot A; Moreau P; Caillon H; Luider TM; Dejoie T; Jacobs JFM; van Duijn MM
Blood Cancer J; 2023 Feb; 13(1):30. PubMed ID: 36828828
[No Abstract] [Full Text] [Related]
11. Mass cytometry as a tool in target validation and drug discovery.
Watson ECR; Baker W; Ahern D; Loi D; Cribbs AP; Oppermann U
Methods Enzymol; 2023; 690():541-574. PubMed ID: 37858540
[TBL] [Abstract][Full Text] [Related]
12. Prognostic marker CD27 and its micro-environmental in multiple myeloma.
Wang X; Luo K; Xu Q; Chi L; Guo Y; Jia C; Quan L
BMC Cancer; 2024 Mar; 24(1):352. PubMed ID: 38504180
[TBL] [Abstract][Full Text] [Related]
13. Analysis of baseline circulating tumor cells integrated with PET/CT findings in transplant-ineligible multiple myeloma.
Ikeda D; Terao T; Oura M; Uehara A; Tabata R; Narita K; Takeuchi M; Machida Y; Matsue K
Blood Adv; 2024 Jan; 8(1):37-46. PubMed ID: 38150271
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM).
Shi L; Yan W; Xu J; Li L; Cui J; Liu Y; Du C; Yu T; Zhang S; Sui W; Deng S; Xu Y; Zou D; Wang H; Qiu L; An G
Ann Hematol; 2024 Apr; 103(4):1305-1315. PubMed ID: 38049586
[TBL] [Abstract][Full Text] [Related]
15. Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index.
Óskarsson JÞ; Rögnvaldsson S; Thorsteinsdottir S; Aspelund T; Gunnarsson SB; Hákonardóttir GK; Sigurðardóttir GÁ; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Sigurðsson JK; Eyþórsson E; Jónsson Á; Viðarsson B; Önundarson PT; Agnarsson BA; Pálmason R; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Harding S; Flores-Montero J; Orfao A; Durie BGM; Love TJ; Kristinsson SY
Blood Cancer J; 2023 Dec; 13(1):177. PubMed ID: 38040702
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: An Italian Monocentric Experience.
Fazio F; Lapietra G; Limongi MZ; Intoppa S; Milani ML; Piciocchi A; Martelli M; Guarini A; Foà R; De Propris MS; Petrucci MT
Mediterr J Hematol Infect Dis; 2023; 15(1):e2023047. PubMed ID: 37705525
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotypic Profile of Multiple Myeloma: A Tertiary Care Centre Experience.
Rath A; Panda T; Dass J; Seth T; Mahapatra M; Tyagi S
J Lab Physicians; 2023 Sep; 15(3):392-398. PubMed ID: 37564229
[No Abstract] [Full Text] [Related]
18. Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future.
Medina-Herrera A; Sarasquete ME; Jiménez C; Puig N; García-Sanz R
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509348
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
